$SGEN News Article - Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV (enfortumab vedotin-ejfv) with KEYTRUDA (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
https://marketwirenews.com/news-releases/seag...12267.html